Skip to main content

Table 1 Baseline clinical characteristics

From: Patency with antiplatelet treatment after vascular access intervention therapy: a retrospective observational study

Characteristic
Number 59
Age 71 (63–79)
Older age (%) 49.2
Sex (male, %) 76.3
Etiology of ESRD (%)
 DN 40.7
 NS 23.7
 CGN 15.3
 ADPKD 1.7
 IgAN 5.1
 Other or unknown 13.6
Smoking history (%) 64.4
DM (%) 57.6
Dyslipidemia (%) 57.6
Major CVD (%) 54.2
 IHD 35.6
 CHF 13.6
 Stroke 8.5
PAD (%) 13.6
RASI (%) 52.5
Statin (%) 49.1
Antiplatelet agents (%) 52.5
 Aspirin 47.5
 Clopidogrel 23.7
 Cilostazol 1.7
 DAPT 20.3
Warfarin (%) 8.4
ESA
 Epoetin α or β (IU/week) 3204.5 ± 2326.0
 Darbepoetin α (μg/week) 40.4 ± 41.2
 CERA (μg/2 week) 62.5 ± 17.7
Hb (g/dl) 10.4 ± 1.4
Platelet (× 103/μl) 18.9 ± 6.7
PT-INR 1.0 ± 0.4
CRP (mg/dl) 0.7 ± 1.4
Dialysis duration (month) 28.6 ± 30.9
AVF anastomosis type (%)
 Radiocephalic 81.4
 Brachiocephalic 16.9
 Radiobasilic 1.7
Quantity of blood flow (ml/min) 192.3 ± 33.6
Flow volume (ml/min)
 Before VAIVT 418.7 ± 362.5
 After VAIVT 843.3 ± 723.2
VAF (%)
 Stenosis/thrombosis 15.3/84.7
Adverse event (%)
 Serious bleeding event
  Intracranial 0
  Gastrointestinal 0
 CVD event after VAIVT
  IHD 11.9
  CHF 5.1
  Stroke 1.7
  1. We defined individuals aged > 71 years as “the older age”
  2. ESRD end-stage renal disease, DN diabetic nephropathy, NS nephrosclerosis, CGN chronic glomerulonephritis, ADPKD autosomal dominant polycystic kidney disease, IgAN IgA nephropathy, DM diabetes mellitus, CVD cardiovascular disease, IHD ischemic heart disease, CHF congestive heart failure, PAD peripheral artery disease, RASI renin–angiotensin–aldosterone system inhibitor, DAPT dual antiplatelet therapy, ESA erythropoiesis-stimulating agent, CERA continuous erythropoietin receptor activator, AVF arteriovenous fistula, VAIVT vascular access intervention therapy, VAF vascular access failure